Excellos Announces Strategic Partnership and Investment from Vitalant
Strategic Partnership With Vitalant to Bring Better Therapies to Patients Partnership to deliver enhanced donor profiles for higher potency cell therapeutics SAN DIEGO. CA, January 17, 2024, – Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO), today announced a new partnership with Vitalant, one of the nation’s largest nonprofit blood and biotherapies […]
Excellos is excited to partner with TC BioPharm to enable novel cell therapies
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced it has selected Excellos, a San Diego based […]
Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego
June 27, 2023; San Diego, California – Excellos Opens Cutting-Edge Cell Therapy GMP Manufacturing Facility in Downtown San Diego. Cell Therapy GMP Manufacturing Facility Excellos, a full-service contract development and manufacturing organization (CDMO) for cell therapy, proudly announces the opening of their cell therapy GMP manufacturing facility in the heart of downtown San Diego. The facility […]
Excellos Launches ‘Excellos 360’ Alongside RUO and GMP Product Portfolio to Reduce Clinical Response Variability
The central aims of Excellos 360 are to reduce clinical response variability and possibly improve outcomes, lower safety liability by allowing effectiveness in lower dosages and reducing the cost of goods associated with advanced therapies. January 17, 2023; San Diego, California – Excellos, the California-based, full-service CDMO, has today announced the launch of ‘Excellos 360’, […]
Single-Cell Analysis of T Cells – Improved Prediction of Disease Risk
The La Jolla researchers are studying how small changes in gene expression can influence the function of immune cells during infection. Single-cell analysis was performed on activated CD4+ T cells from 89 healthy donors. It turns out that the old adage of “one gene, one protein” is not precisely true. In reality, as research on […]
Stem Cell Transduction Efficiency – Managing Donor Variance
Gene therapy, and in particular, therapy involving genetically modified stem cells, is one of the most promising methods for treating genetic disease and defects, and has therefore become a popular focus of research and development. In recent years, using adenoviral vectors to deliver modified genes has become standard practice. Adeno-associated viruses (AVVs) are easy to […]
Genesis San Diego Secures Excellos, Marking Downtown San Diego’s Second-Ever Life Sciences Lab Lease
CHARLOTTE, N.C. and SAN DIEGO, Oct. 26, 2022 /PRNewswire/ — Barings, one of the world’s largest diversified real estate investment managers, along with Phase 3 Real Estate Partners and Bain Capital Real Estate, announced today that their joint venture has secured Excellos as a tenant at Genesis San Diego, a premier Class A life science […]
Single-Cell Immune Profiling Reveals Remarkable Changes Associated with COVID-19
Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] Great strides have been made in fighting the SARS-CoV-2 virus, the most noteworthy being the development and distribution of the COVID-19 vaccine. However, we must keep […]
Trogocytosis – A Case of T cell Identity Theft Offers Essential Clue to Solving MS
A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of Neuropathology in Gottingen, Germany, describe new research that could help doctors treat MS. [1] The key […]
Efficient Isolation of Antigen-Specific B Cells
Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at the forefront of vaccine research as scientists continue to develop new treatments to fight cancer, autoimmunity, and infectious disease. […]